Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Search Results

Refine Your Search

By Sector

Sort by: Date|Relevance

Analyst Upgrade Ignites Duchenne's Muscular Dystrophy Research Firm's Shares

Solid Biosciences' shares are up by more than 40% today after Chardan Capital Markets upgraded the firm's shares from "neutral" to "buy" and raised its price target from $7.50 to $10.00/share. Duchenne muscular dystrophy (DMD) research firm Solid Biosciences ...
Streetwise Reports | August 20, 2019 |

Olympia Financial Group: With us, it's personal

Olympia Financial Group conducts most of its operations through Olympia Trust Company, providing trust and custodial services to investors in Canada’s private capital markets. The company serves clients from across Canada and is a significant player i...
Brieanna McCutcheon | December 12, 2022 |

Gold royalty stock might be better than an ETF

It doesn’t look like the economy is going to be stable any time soon. Unrest in Europe, looming U.S. deficit questions and poor unemployment are just some of the factors keeping the markets in a state of flux. As we’ve told you before, wat...
Justin Dove | October 28, 2012 |

Buzz on the Bullboards: The Fastest Moving Up & Comers

In recent days, weeks, even months, markets on both sides of the 49 th parallel have been erratic as volatility has returned with a vengeance. Investors continue to gather at Stockhouse. What is a buying opportunity for one investor is a "selling window" for another. ...
Stockhouse Editorial | September 29, 2021 |

Powering the Green Energy Revolution: Discovering New Nickel Deposits in Canada

Here’s a green energy, electric vehicle metals play worth getting to know… now. Metal Energy Corp. ( TSX-V.MERG , Forum ) is a high-potential exploration & development company focussed on high-quality nickel projects in Canada’s prolific ...
Dave Jackson | January 24, 2022 |

Allakos Shares Double on AK002 Phase 2 Results and Earnings

Allakos Inc. shares are soaring today as the company reported Q2/19 earnings and announced positive results from its phase 2 study for its AK002 inhibitor used in the treatment of eosinophil and mast cell related diseases. Clinical stage biotech company Allak...
Streetwise Reports | August 7, 2019 |

Fiscal Year 'Reads Well' for Regenerative Medicine Company

The firm's final quarter and full-year results are reviewed in a Ladenburg Thalmann report. In an Aug. 30 research note, Ladenburg Thalmann analyst Jeffrey Cohen reported Mesoblast Ltd.'s (MESO:NASDAQ; MSB:ASX) financial results for Q4/19 and fiscal year 2019 (FY19)...
Streetwise Reports | September 5, 2019 |

Barrick-Newmont Goldcorp Joint Venture Leads to 'Cornucopia of Opportunities'

The synergies, potential and realized, that resulted from combining these two companies' Nevada assets are discussed in a BMO Capital Markets report. In a Sept. 23 research note, BMO Capital Markets analyst Andrew Kaip reported his impressions from 2.5 days spent with...
Streetwise Reports | September 27, 2019 |

Iovance Biotherapeutics Shares Rise 12% on Updated Phase 2 Melanoma Study Results

Shares of Iovance Biotherapeutics traded 12% higher today after the firm reported updated clinical data from its phase 2 lifileucel metastatic melanoma trial. Just a few days after reporting third quarter 2019 earnings, late-stage biotechnology company Iovance Biothe...
Streetwise Reports | November 12, 2019 |

Canada Asset 'Sale Helps Company Focus on Mexico'

The specifics and benefits of the transaction are addressed in a ROTH Capital Partners report. In a Nov. 22 research note, ROTH Capital Partners analyst Joe Reagor reported that Avino Silver & Gold Mines Ltd. (ASM:TSX.V; ASM:NYSE.MKT; GV6:FSE) agreed to sell its Bra...
Streetwise Reports | December 2, 2019 |
1 2 3 4 5 6